Marathon and Medline partner to distribute ZiNGO handheld device

18 February 2015 (Last Updated February 18th, 2015 18:30)

Marathon Pharmaceuticals has partnered with Medline Industries to market and distribute ZiNGO (lidocaine hydrochloride monohydrate, 0.5mg) powder intradermal injection system, a needle-free, easy-to-use device.

Marathon Pharmaceuticals has partnered with Medline Industries to market and distribute ZiNGO (lidocaine hydrochloride monohydrate, 0.5mg) powder intradermal injection system, a needle-free, easy-to-use device.

The device is designed to deliver a topical local anesthetic to manage venous access pain of venipuncture and peripheral intravenous cannulation in children in just one to three minutes.

The collaboration uses Marathon's expertise in specialty drug development and manufacturing, and Medline's strengths as a global distributor of medical supplies and clinical solutions.

Currently in use at several major children's and academic hospitals, ZiNGO is a handheld device that delivers a 0.5mg dose of powdered lidocaine into the skin through a needle-free helium-powered delivery system.

Indicated for external use on intact skin only, ZiNGO is sterile, designed for single-use, and does not need to be refrigerated.

Connecticut Children's Medical Center division head of Pain and Palliative Medicine William Zempsky said: "Physicians look to innovative medical products to help ease patient discomfort in pursuit of their goal to deliver optimal care and to achieve the highest level of patient satisfaction.

"Indicated for external use on intact skin only, ZiNGO is sterile, designed for single-use, and does not need to be refrigerated."

"I was pleased to be a part of this important initiative for reducing pain and discomfort related to venipuncture and IV cannulation in children."

Both companies aim to offer high level of patient care through new products, technologies and services.

Marathon Pharmaceuticals vice-president of Commercial Operations Tom Larson said: "By providing quality services, clinical solutions and logistical expertise, Medline is the preferred provider for leading healthcare organisations, and we are proud to work with its team to make ZiNGO available across the nation."

ZiNGO is indicated for use on intact skin to offer topical local analgesia prior to venipuncture or peripheral intravenous cannulation in children from the age of three to the age of 18.

Medline president Nutrition and Pharmaceuticals division Luke Stevens said: "We're excited to be joining forces with Marathon Pharmaceuticals to bring healthcare professionals a unique lidocaine drug delivery system to help manage IV start and blood draw pain.

"As our customers require other options to help improve patient outcomes and satisfaction, they can be confident in our never-ending search for proven solutions."

ZiNGO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type.